Search Results for: cnsp

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for cancers in the brain and central nervous system, reported a Q2 2025 net loss of $2.4 million, slightly improved from $2.5 million in Q2 2024, driven by reduced Berubicin trial costs. R&D expenses rose to $1.2 million from $1.1 million on preparation for a TPI … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company developing novel treatments for primary and metastatic cancers in the brain and central nervous system, announced it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, taking place virtually Aug. 19–21, 2025. To view the full press release, visit https://ibn.fm/JKPUq About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Webull Financial Biotech/MedTech Webinar Series”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company focused on treating brain and CNS cancers, will implement a 1-for-12 reverse stock split effective July 22, 2025. Its common stock will continue trading under the symbol CNSP but with a new CUSIP number: 18978H508. Each 12 shares of common stock will convert into one, with proportional adjustments … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22”

CNS Pharmaceuticals (NASDAQ: CNSP) announced that Chief Medical Officer Sandra Silberman, M.D., Ph.D., will present at the Brain Tumor Biotech Summit hosted by Lenox Hill Hospital’s Department of Neurosurgery on June 5, 2025. Her presentation, titled “The Future and Promise of TPI 287,” will highlight CNS’s brain-penetrating taxane candidate, which has shown efficacy in glioblastoma … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit”

CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. TPI 287, a microtubule-stabilizing abeotaxane, has shown potential to cross the blood-brain barrier and demonstrated encouraging results in a Phase 1 glioblastoma trial, including 3 complete … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications”

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D spending. Despite Berubicin missing its primary endpoint in a glioblastoma multiforme (GBM) trial, the drug demonstrated safety and comparable efficacy, guiding future analysis. The … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position”

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present at the 18th Annual European Life Sciences CEO Forum in Zurich on Feb. 26, 2025, at 3:20 p.m. CET / 9:20 a.m. EST; management will also be available for one-on-one meetings with registered investors, and a video webcast of the presentation will be accessible … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum”

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the Virtual Investor Top 5 for ‘25 On-Demand Conference, where CEO John Climaco outlined five key reasons for investors and industry peers to follow the company in 2025. The presentation focused on CNS Pharmaceuticals’ advancements in developing treatments for primary and metastatic brain and central nervous system … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for brain and central nervous system cancers, will host a Virtual Analyst & Investor Day on December 11 from 11:30 a.m. to 1 p.m. ET. The event will feature presentations by the company’s leadership team, including CEO John Climaco, Chief Medical Officer Dr. Sandra Silberman, and … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11”